Friday, February 03, 2012

Should All IPF Patients Be Treated for GERD?

When I was diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and told I had about 2 years to live I can remember frantically searching for anything that might prolong my life beyond that time, such as trials of experimental drugs that I could enroll in. I imagine this study is something anyone with IPF would want to participate in.

Gastroesophageal Reflux Therapy Is Associated With Longer Survival in Patients With Idiopathic Pulmonary Fibrosis

by Nicholas Gross, MD, PhD Medscape Pulmonary Medicine

Study Summary

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) is often present and may contribute to disease progression, possibly due to microaspiration of reflux gastric contents.[1] Some small studies have suggested that treatment of GERD may slow the progression of IPF. The present much larger study attempts to determine the frequency of GERD in patients with IPF and whether medical or surgical treatments are associated with prolonged survival. The study was observational and included data on the treatment and duration of survival of 204 patients from 2 major academic medical centers.

GERD was present by history in 34%-45% of participating IPF patients; 47% received GERD medications and 5% had Nissen fundoplication surgery. Median survival time of patients who received a diagnosis of GERD was 1499 days vs 920 days for those who were not diagnosed with GERD (P < .01). However, patients who received treatment for GERD, either a proton-pump inhibitor or histamine blocker, survived significantly longer than those who did not (median of 1967 days vs 896 days [P < .01]). Nissen fundoplication prolonged survival similarly. After adjustment for potentially confounding factors, the only predictor of prolonged survival apart from lung function was GERD therapy. Viewpoint

The prognosis of IPF is as dire as that of lung cancer, with a median survival between 2 and 3 years.[2] Its cause and pathophysiology are unclear, and current therapies provide limited benefit.[3] Thus, a treatment that may prolong survival, especially one that is already available and the safety of which is known, is of considerable interest. Lee and colleagues' study goes some of the distance to fulfilling that need. The results suggest that any of the currently available GERD treatments can prolong median survival by almost 3 years, namely by a factor of more than 2.

But the study has some limitations. First, it was an observational study rather than a prospective, randomized treatment study. The 2 groups, those who received GERD treatment and those who did not, seemed to be reasonably well-balanced; however, the decision to treat GERD may not have been uniformly applied. There may also be other unknown confounding factors. Second, it would have been interesting to know whether GERD medications only benefited patients who had symptoms or a diagnosis of GERD, but that analysis was not reported. The study also doesn’t explore whether a patient with IPF must have a diagnosis of GERD to benefit from GERD therapy. Third, the observation that patients who had symptoms or a diagnosis of GERD had longer survival than those who did not seems to contradict the hypothesis that GERD contributes to IPF progression.

Despite these limitations, the potential ability to prolong survival of patients with this aggressive disease, the need for IPF treatments, and the safety and general availability of oral treatments for GERD all argue in favor of their greater use in IPF. The substantial prolongation of life in this study speaks for itself. Clearly, a prospective trial with a randomized, double-blind treatment assignment would be needed to confirm the benefit but may pose ethical concerns.

“You Have the Power to Donate Life – to become an organ and tissue donor Sign-up today!
Tell Your Loved Ones of Your Decision”
Australia, register at Australian Organ Donor Register
New Zealand, register at Organ Donation New Zealand
South Africa,
United States,
United Kingdom, register at NHS Organ Donor Register
Your generosity can save or enhance the lives of up to fifty people with heart, kidneys, liver, lungs, pancreas and small intestine transplants (see allotransplantation). One tissue donor can help by donating skin, corneas, bone, tendon, ligaments and heart valves
Has your life been saved by an organ transplant? "Pay it forward" and help spread the word about the need for organ donation - In the U.S. another person is added to the national transplant waiting list every 11 minutes and 18 people die each day waiting for an organ or tissue transplant. Organs can save lives, corneas renew vision, and tissue may help to restore someone's ability to walk, run or move freely without pain. Life Begins with You.

No comments: